IL13 and helminthiasis: Inhibition of systemic fatty acid oxidation (FAO) by treatment of etomoxir in vivo, but not systemic inhibition of glycolysis, reduced intestinal ILC2 accumulation and production of IL-13 and IL-5 in response to helminth infection [61].